Bartlett & Co’s Aralez Pharmaceuticals Inc. ARLZ Stock Holding History

Bartlett & Co’s Portfolio ARLZ Stock Details ARLZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-272	Closed	–	–	783
2017 Q4	$0	Hold	272	–	–	﹤0.01%	720
2017 Q3	$1K	Hold	272	–	–	﹤0.01%	675
2017 Q2	$0	Hold	272	–	–	﹤0.01%	724
2017 Q1	$1K	Hold	272	–	–	﹤0.01%	698
2016 Q4	$1K	Hold	272	–	–	﹤0.01%	698
2016 Q3	$1K	Hold	272	–	–	﹤0.01%	694
2016 Q2	$1K	Buy	+272	New	+$1.03K	﹤0.01%	724

Other funds holding ARLZ

PCM

PAR Capital Management Boston, Massachusetts $3.45B AUM 28.5% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

DZ Bank Frankfurt Am Main, Germany $113B AUM 36.92% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

BAS

Brown Advisory Securities Baltimore, Maryland $27.3M AUM 10.67% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Salzhauer Michael $212M AUM 20.86% 1-Year Est. Return

Bartlett & Co's ARLZ Position: Q1 2018 in Review

Bartlett & Co sold out of Aralez Pharmaceuticals Inc. (ARLZ) in Q1 2018, closing a stake of 272 shares.

Bartlett & Co first reported a position in ARLZ in Q2 2016 and held it in 7 quarters. The position peaked at $1K in Q3 2017. 56 funds tracked by Wall St. Rank hold ARLZ as of Q1 2018.

Bartlett & Co reported no remaining Aralez Pharmaceuticals Inc. position as of Q1 2018 after selling out during the quarter.
Bartlett & Co sold 272 Aralez Pharmaceuticals Inc. shares in Q1 2018.
Bartlett & Co first reported a position in Aralez Pharmaceuticals Inc. in Q2 2016 and held it in 7 quarters.
Bartlett & Co's Aralez Pharmaceuticals Inc. position peaked at $1K in Q3 2017.
56 funds tracked by Wall St. Rank held Aralez Pharmaceuticals Inc. as of Q1 2018.

Based on Bartlett & Co's 13F filing for Q1 2018, filed 25 Apr 2018.